Autopsy report · NCT05682170
Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Ran for about 1 year 8 months before it stopped.
- 40 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
- Sponsor type
- Industry
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- ZN-d5 ZN-c3; ZN-c3
- Participants
- 40
- Sites
- 13
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.